Alamar Biosciences, Inc.
Alamar Biosciences, Inc.
Alamar Biosciences Inc is a proteomics company specializing in protein detection and analysis. The company has developed proprietary NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology, which forms the foundation of its Precision Proteomics platform. This platform enables the detection and quantification of protein biomarkers from a single sample with ultra-high sensitivity and specificity, even from minimal biofluid volumes. Operating as a single-segment business, the company focuses on developing a highly sensitive proteomic liquid biopsy platform and markets instruments, consumables, and services to facilitate early disease detection. Key product offerings include NULISAseq Panels and NULISAqpcr Assays.
When is the Alamar Biosciences, Inc. IPO expected?
Alamar Biosciences, Inc. has already gone public. It listed on April 17, 2026.
What is Alamar Biosciences, Inc.'s valuation?
Alamar Biosciences, Inc.'s estimated valuation is approximately $191M. It operates in the Life Sciences Tools & Services sector. The final valuation will depend on IPO pricing and market demand.
Can retail investors participate in the Alamar Biosciences, Inc. IPO?
U.S. IPOs are typically allocated to institutional investors first. Retail investors can purchase shares on NASDAQ Global Select after listing. Some brokerages offer IPO access programs for pre-IPO allocation.
What does Alamar Biosciences, Inc. do?
Alamar Biosciences Inc is a proteomics company specializing in protein detection and analysis. The company has developed proprietary NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology, which forms the foundation of its Precision Proteomics platform. This platform enables the detection and quantification of protein biomarkers from a single sample with ultra-high sensitivity and specificity, even from minimal biofluid volumes. Operating as a single-segment business, the company focuses on developing a highly sensitive proteomic liquid biopsy platform and markets instruments, consumables, and services to facilitate early disease detection. Key product offerings include NULISAseq Panels and NULISAqpcr Assays.